New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 325.23mg equivalent to darunavir 300 mg - film coated tablet - 300 mg - active: darunavir ethanolate 325.23mg equivalent to darunavir 300 mg excipient: crospovidone magnesium stearate opadry orange 85f13962 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 162.52mg equivalent to darunavir 150 mg - film coated tablet - 150 mg - active: darunavir ethanolate 162.52mg equivalent to darunavir 150 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate opadry white 85f18422 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 433.64mg equivalent to darunavir 400 mg - film coated tablet - 400 mg - active: darunavir ethanolate 433.64mg equivalent to darunavir 400 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate opadry orange 85f93377 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 650.46mg equivalent to darunavir 600 mg - film coated tablet - 600 mg - active: darunavir ethanolate 650.46mg equivalent to darunavir 600 mg excipient: crospovidone magnesium stearate opadry orange 85f13962 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 81.31mg equivalent to darunavir 75 mg - film coated tablet - 75 mg - active: darunavir ethanolate 81.31mg equivalent to darunavir 75 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate opadry white 85f18422 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 867.28mg equivalent to darunavir 800 mg - film coated tablet - 800 mg - active: darunavir ethanolate 867.28mg equivalent to darunavir 800 mg excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate opadry red 85f150004 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir ethanolate 400 mg - prezista® , co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment-naïve and treatment-experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients. prezista, co-administered with ritonavir (prezista/ritonavir), and with other antiretroviral agents, is indicated for the treatment of hiv infection in pediatric patients 6 years of age and older [see use in specific populations (8.4) ]. this indication is based on 24-week analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment-experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric patients, the following poi

Canada - English - Health Canada

auro pharma inc - darunavir (darunavir propylene glycolate) - tablet - 400mg - darunavir (darunavir propylene glycolate) 400mg - hiv protease inhibitors

Canada - English - Health Canada

auro pharma inc - darunavir (darunavir propylene glycolate) - tablet - 600mg - darunavir (darunavir propylene glycolate) 600mg - hiv protease inhibitors

Canada - English - Health Canada

auro pharma inc - darunavir (darunavir propylene glycolate) - tablet - 800mg - darunavir (darunavir propylene glycolate) 800mg - hiv protease inhibitors